J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

November 14, 2019

Study Completion Date

January 3, 2021

Conditions
Prostate Cancer
Interventions
DRUG

huJ591

HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of \<5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.

Trial Locations (1)

10021

Weill Cornell Medical College, New York

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER

NCT02552394 - J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts | Biotech Hunter | Biotech Hunter